HUM.US Weekly · 2026-W32
Humana rose 5.8% this week to $385, with valuations near three-year lows. While institutional ratings remain bullish with a $413 price target, the company cut full-year earnings guidance at earnings release, even as large-cap funds posted net outflows and retail stepped in. This “near-term data solid but forward guidance down” contradiction continues to be priced by the market.
Market Performance
Closing at $385.00 this week, versus $363.86 at end of last week (7-31), the gain is 5.79%. Intra-week high $385.66, low $353.69, representing a swing of roughly 8.7%.
Trading volume snapshot: average daily volume 1.36M shares, weekly turnover rate 1.17%. Volume sits within normal historical range, no obvious spike. Pattern-wise, price consolidated in the $353–$375 band before touching the week’s low ($353.69) on Wednesday, then bounced Tuesday to Friday with gradual buying pressure into the week-end, though the rally stayed measured.
Valuation and Earnings
Current P/E stands at 34.48x, placing it in the 10.65th percentile over three years—a multi-year trough. Yet this valuation still trades ~33% above industry median (25.98x), signaling the market still prices a premium for the company’s earnings power.
Q2 2026 results: EPS $5.73, +27.05% YoY; operating revenue $40.87B, +26.2% YoY; net profit +27.6% YoY. Sequentially, Q2 EPS $5.73 trails Q1’s $9.83—a slide quarter-to-quarter. Current consensus EPS for full year: $12.33 (median $12.51); Q2 has now delivered ~46% of annual expectations.
A critical note: despite Q2 beating expectations, the company lowered 2026 earnings guidance at the earnings release, sparking an 8%+ plunge in stock price. The market has since digested this headwind week-on-week, underpinned by the recovery we observe.
Institutional & Capital Flows
Institutional view: 11 firms rate it “Strong Buy,” 13 “Hold,” 1 “Sell,” totaling 26 analysts. Consensus rating: “Buy” with an average price target of $413.09—7.3% upside from current. Ratings updated 8-7, reflecting the latest digest of earnings and guidance shifts. Bear in mind ratings are backward-looking signals; current risks may already be partially baked into price.
Capital flows: This week, large-cap funds showed net outflows of 465.97 points; mid-cap funds outflows of 164.62 points. In contrast, small-cap (retail) funds posted inflows of 170.20 points. Institutional and retail directions diverge starkly—institutions stepping back, retail stepping in at relative lows. This fissure warrants close watch.
This Week’s News
The healthcare sector posted solid performance this week, buoyed by optimistic earnings expectations across the industry. Humana, a sector heavyweight, outperformed peers in a strong trading session. A subsidiary, iCare, also secured a home care contract in southeast Wisconsin, adding growth momentum to its care services unit.
Analyst sentiment showed shifts: one analyst previously bearish moved to neutral this week, and Bank of America upgraded to “Buy.” Yet these adjustments are reactions to earnings and market moves—not forward-looking refinement of management’s downside concern for H2.
Key news items from the week:
- Humana outperforms peers in strong trading session
- Healthcare sector up on upbeat profit outlook—Healthcare review
- Humana analyst no longer holds bearish stance; here are Wednesday’s five top rating upgrades
- Humana (NYSE: HUM) upgraded to Buy at Bank of America
- Humana subsidiary iCare secures home care contract in SE Wisconsin
- Humana Q2 2026 earnings: Revenue $40.9B, EPS $5.73—10-Q summary
- Humana Q2 2026 net profit up 27.6% to $693M; revenue up 26.2% to $40.87B
- Humana plunges 8%+ on 2026 earnings guidance cut
- Humana’s strong quarterly results fail to impress
- Humana profit growth but cuts 2026 EPS guidance while maintaining adjusted earnings and revenue outlook; stock declines
Summary
This week’s Humana trade reflects three interlocking signals in flux:
Alignment: Low valuation (11th percentile) and bullish institutional view (11 strong buys) both point to defensive value. Q2’s 26%+ growth in revenue and profit underscores that appeal.
Contradiction: Yet the company flagged doubt about H2 by lowering guidance, prompting large-cap fund exits this week. By contrast, retail steps in at relative lows—a “institution fleeing, retail catching” split. Such divergence often signals the market is still in the repricing phase.
Key risk: Whether the guidance cut’s root causes (medical costs, MA plan pressures) are already reflected in the 7.3% upside price target remains uncertain. Near-term, retail’s continued stepping-in power becomes the critical prop for price support.